ESMO 2026
Syneos Health at ESMO 2026: Moving What Matters Forward in Oncology
Oncology innovation is moving at extraordinary speed. Emerging modalities, biomarker-driven development, artificial intelligence and increasingly complex clinical trials are creating new possibilities for patients and new strategic decisions for sponsors. Determining which early development decisions matter most and what strategies will create the strongest path to clinical and commercial success has never been more important.
At the 2026 European Society for Medical Oncologists (ESMO) annual conference Syneos Health is bringing together deep oncology expertise, predictive intelligence and global development capabilities to help sponsors turn scientific complexity into confident action at every stage of the drug development journey.
From making smarter decisions ahead of proof of concept to informing patient identification and selection and supporting multi-country trial at scale, we’re focused on moving what matters forward.
Moving Complex Oncology Development Forward
Confidence Ahead of Proof of Concept
Our oncology experts combine medical rigor with strategic foresight to help sponsors interpret emerging data, optimize dose and development strategies and apply adaptive trial designs from first-in-human studies through proof of concept.
Predictive Oncology Intelligence
By combining predictive analytics, AI-enabled technologies and deep oncology expertise, we help sponsors assess promising tumor types and patient populations, inform biomarker strategies, support protocol optimization and evaluate development opportunities and risks.
Built to Scale Breakthrough Science
Our experience spans the modalities shaping the future of cancer treatment, including ADCs, radiopharmaceuticals, bispecific antibodies and cell and gene therapies. We bring together complex-modality expertise, biomarker-driven development, MRD strategies and global execution capabilities to help sponsors execute complex multi-country trials while navigating scientific, operational and regulatory complexity.
Value Creation From the Start
Clinical decisions made today can influence differentiation, evidence requirements, access and adoption tomorrow. By connecting clinical development with commercial, value and access and evidence-generation expertise earlier, we help sponsors make decisions designed to strengthen asset potential throughout development.
See How Syneos Health Shows Up for ESMO 2026:
Scientific complexity should go hand-in-hand with meaningful progress in clinical oncology trials.
Executive Briefing | From ASCO to ESMO: Four Strategic Shifts Shaping Oncology in 2026
Podcast Series | The Syneos Health Podcast: Early Signals
Blog | European Oncology Clinical Trials: Site Selection Beyond Traditional Markets
